

PHARMACEUTICAL LISTING

2009 BUYERS GUIDE

» This listing, organized by indication, is a quick way to find commonly used respiratory and sleep drugs. Consult the manufacturer's full prescribing information before administering any drug to a patient.

ALPHA-₁ ANTITRYPSIN DEFICIENCY

Aralast™
Generic: Alpha-₁ Proteinase Inhibitor (Human)
Description: Purified human alpha-₁ antitrypsin
Manufacturer: Baxter Healthcare
Indication: Chronic augmentation therapy in patients having congenital deficiency of alpha-1 antitrypsin with clinically evident emphysema
Recommended dose: 60 mg/kg body weight once weekly

Aralast-NP™
Generic: Alpha-₁ Proteinase Inhibitor (Human)
Description: Purified human alpha-₁ antitrypsin
Manufacturer: Baxter Healthcare
Indication: Chronic augmentation therapy in patients having congenital deficiency of alpha-₁ antitrypsin with clinically evident emphysema
Recommended dose: 60 mg/kg body weight once weekly

Prolastin®
Generic: Alpha-₁ Proteinase Inhibitor (Human)
Description: Purified human alpha-₁ antitrypsin
Manufacturer: Talecris Biotherapeutics Inc.
Indication: Chronic replacement therapy for patients with congenital deficiency of alpha-₁ antitrypsin with clinically demonstrable panacinar emphysema
Recommended dose: 60 mg/kg body weight once weekly

Zemaira™
Generic: Alpha-₁ Proteinase Inhibitor (Human)
Description: Purified human alpha-₁ antitrypsin
Manufacturer: CSL Behring LLC.
Indication: Chronic augmentation and maintenance therapy in individuals with alpha-₁ antitrypsin deficiency and clinical evidence of emphysema
Recommended dose: 60 mg/kg body weight once weekly

ASTHMA

Accolate® Tablets
Generic: Zafirlukast
Description: Leukotriene receptor antagonist
Manufacturer: AstraZeneca Pharmaceuticals LP
Indication: Prophylaxis and continuous treatment of asthma in patients 5 years and older
Recommended dose: Adults and children 12 years and older: 20 mg bid (oral); children 5 to 11 years: 10 mg bid (oral)

AccuNeb™ Solution for Inhalation
0.021% and 0.042%
Generic: Albuterol Sulfate Inhalation Solution 0.021% and 0.042%
Description: Short-acting beta₂-agonist
Manufacturer: Dey
Indication: Relief of bronchospasm in patients 2 to 12 years with reversible obstructive airway disease
Recommended dose: 0.63mg or 1.25 mg (one 3 mL unit-dose vial) tid or qid by nebulization

Advair™ Diskus® 100/50, 250/50, 500/50
Generic: Fluticasone propionate and salmeterol xinafoate
Description: Combination product
Manufacturer: GlaxoSmithKline
Indication: Long-term, twice-daily maintenance treatment of asthma in patients 4 years and older. ADVAIR DISKUS 250/50 is indicated for the twice-daily maintenance treatment in patients with COPD associated with chronic bronchitis. This product shouldn't be used for acute exacerbations.
Recommended dose: One inhalation bid (a.m. and p.m., approx. 12 hours apart)

Advair® Diskus HFA 45/21, 115/21, 230/21
Generic: Fluticasone propionate and salmeterol xinafoate
Description: Combination product
Manufacturer: GlaxoSmithKline
Indication: Long-term, twice-daily maintenance treatment of asthma in patients 12 years and older. This product should not be used for acute exacerbations.
Recommended dose: Two inhalations bid (a.m. and p.m., approx. 12 hours apart)

Albuterol Inhalation Aerosol
Note: A limited number of CFC inhalers remain available; pharmacies can sell these products

after the Dec. 31, 2008 phaseout deadline if they still have remaining stock.

Description: Short-acting beta₂-agonist
Manufacturer: Various
Indication: Prevention and relief of bronchospasm in patients 4 years and older with reversible obstructive airway disease, and prevention of exercise-induced bronchospasm
Recommended dose: Two inhalations q 4 to 6 hours

Albuterol Sulfate Inhalation Solution 0.042%
Description: Short-acting beta₂-agonist
Manufacturer: Various
Indication: Relief of bronchospasm in patients 2 to 12 years with reversible obstructive airway disease
Recommended dose: 1.25 mg (one 3 mL unit-dose vial) tid or qid by nebulization

Albuterol Sulfate Inhalation Solution 0.5%
Description: Short-acting beta₂-agonist
Manufacturer: Various
Indication: Relief of bronchospasm in patients 2 years and older with reversible obstructive airway disease and acute attacks of bronchospasm
Recommended dose: 2.5 mg (as 0.5 mL diluted in normal saline or other suitable agent) tid or qid by nebulization

Albuterol Sulfate Inhalation Solution 0.083%
Manufacturer: Various
Description: Short-acting beta₂-agonist
Indication: Relief of bronchospasm in patients 2 years and older with reversible airway disease and acute attacks of bronchospasm
Recommended dose: 1 vial tid or qid by nebulization

Albuterol Sulfate Tablets
Manufacturer: Various
Description: Short-acting beta₂-agonist
Indication: Relief of bronchospasm in patients 6 years and older with reversible airway disease and acute attacks of bronchospasm
Recommended dose: One tablet (2 mg or 4 mg) orally 3 to 4 times daily

Albuterol Sulfate Extended Release Tablets
Manufacturer: Mylan
Description: Short-acting beta₂-

agonist
Indication: Relief of bronchospasm in patients 6 years and older with reversible airway disease and acute attacks of bronchospasm
Recommended dose: One tablet (4 mg or 8 mg) every 12 hours

Alvesco®
Generic: Ciclesonide
Manufacturer: Nycomed
Description: Non-halogenated glucocorticoid prodrug
Indication: Maintenance treatment of asthma as prophylactic therapy in patients 12 years and older
Recommended dose: One puff (80 mcg or 160 mcg) once daily

Asmanex® Twisthaler Inhalation Powder
Generic: Mometasone furoate
Description: Inhaled corticosteroid
Manufacturer: Schering Corp.
Indication: Maintenance treatment of asthma as prophylactic therapy for patients 4 years and older
Recommended dose: Initial treatment, 1 inhalation (220 mcg per inhalation) QD (once daily) in the evening. Dosage may be increased to 2 inhalations QD (once daily). For patients maintained on oral corticosteroids: 2 inhalations (440 mcg) bid.

Azmacort® Inhalation Aerosol
Generic: Triamcinolone acetonide
Description: Inhaled corticosteroid
Manufacturer: Abbott Laboratories
Indication: Maintenance treatment of asthma as prophylactic therapy
Recommended dose: Adults: 2 inhalations (200 mcg) tid or qid, or 4 inhalations (400 mcg) bid; 6 to 12 years: 1 or 2 inhalations (100 to 200 mcg) tid or qid, or 4 inhalations (200 to 400 mcg) bid

Cromolyn Sodium Inhalation Solution USP
Description: Mast cell stabilizer
Manufacturer: Dey
Indication: Management of bronchial asthma
Recommended dose: One vial qid by nebulization

Flovent® HFA Inhalation Aerosol
44 mcg, 110 mcg, 220 mcg
Generic: Fluticasone propionate HFA
Description: Inhaled corticosteroid
Manufacturer: GlaxoSmithKline
Indication: Maintenance treatment of asthma as prophylactic therapy in patients 4 years and older
Recommended dose: 2 puffs bid

Foradil® Aerolizer™

Generic: Formoterol fumarate inhalation powder

Description: Long-acting beta₂-agonist

Manufacturer: Schering Corp.

Indication: Long-term, twice-daily maintenance treatment of asthma and prevention of bronchospasm in patients 5 years and older with reversible obstructive airways disease, and acute prevention of exercise-induced bronchospasm in patients 12 years and older. This product should not be used for acute exacerbations.

Recommended dose: The contents of one capsule (12 mcg) by inhalation every 12 hours

Intal® Inhaler

Generic: Cromolyn sodium for oral inhalation

Description: Inhaled mast cell stabilizer

Manufacturer: King Pharmaceuticals Inc.

Indication: Prophylactic agent in the management of patients with bronchial asthma; also may be effective in some patients with exercise-induced bronchospasm

Recommended dose: Patients 5 years and older: 2 puffs qid

Maxair™ Autohaler™

Generic: Pirbuterol acetate inhalation aerosol

Description: Short-acting beta₂-agonist

Manufacturer: Graceway Pharmaceuticals LLC

Indication: Prevention and reversal of bronchospasm in patients 12 years and older with reversible bronchospasm

Recommended dose: Two inhalations (400 mcg) q 4 to 6 hours; one inhalation (200 mcg) q 4 to 6 hours may suffice for some patients

Metaproterenol Sulfate (available as oral syrup, 10 mg and 20 mg tablets)

Description: Short-acting beta₂-agonist

Manufacturer: Various

Indication: For bronchial asthma and reversible bronchospasm associated with bronchitis and emphysema

Recommended dose: Oral dosing also would be tid or qid

ProAir® HFA Inhalation Aerosol

Generic: Albuterol sulfate

Description: short-acting beta₂-agonist

Manufacturer: Teva Specialty Pharmaceuticals LLC

Indication: Treatment and prevention of bronchospasm with reversible obstructive airways disease and prevention of exercise-induced bronchospasm in patients 4 years and older

Recommended dose: For patients 12 years and older: two inhalations repeated every 4 to 6 hours. For exercise-induced bronchospasm prevention, patients 12 years or older: two inhalations 15 to 30 minutes before exercise.

Proventil® HFA Inhalation Aerosol

Generic: Albuterol sulfate

Description: Short-acting beta₂-agonist

Manufacturer: Schering-Plough

Indication: Treatment and prevention of bronchospasm with reversible obstructive airways disease and prevention of exercise-induced bronchospasm in patients 4 years and older

Recommended dose: Two inhalations q 4 to 6 hours

Pulmicort Respules™ 0.25 mg and 0.5 mg

Generic: Budesonide inhalation suspension

Description: Inhaled corticosteroid

Manufacturer: AstraZeneca

Indication: Maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years

Recommended dose: One respule once or twice daily as directed by nebulization

Pulmicort Flexhaler™

Generic: Budesonide inhalation powder

Description: Inhaled corticosteroid

Manufacturer: AstraZeneca

Indication: Maintenance treatment of asthma as prophylactic therapy in patients 6 years and older. This product should not be used for acute exacerbations.

Recommended dose: Inhalation of 90 mcg to 360 mcg twice daily

QVAR™ Inhalation Aerosol 40 mcg and 80 mcg per actuation

Generic: Beclomethasone dipropionate HFA inhalation aerosol

Description: Inhaled corticosteroid

Manufacturer: Teva Specialty Pharmaceuticals LLC

Indication: Maintenance treatment of asthma as prophylactic therapy in patients 5 years and older

Recommended dose: Low dose: 80 to 160 mcg as 40 to 80 mcg BID; medium dose: 160 to 320 mcg; high dose: 320 mcg bid (the highest

dose recommended dosage). For children ages 5 to 11 years: starting dose of 40 mcg bid up to 80 mcg bid maximum recommended

Serevent® Diskus

Generic: Salmeterol xinafoate inhalation powder

Description: Long-acting beta₂-agonist

Manufacturer: GlaxoSmithKline

Indication: Long-term, twice-daily maintenance treatment of asthma and in prevention of bronchospasm in patients 4 years and older with reversible obstructive airway disease; also for long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. This product should not be used for acute exacerbations.

Recommended dose: Patients 4 years and older: one inhalation (50 mcg) bid (a.m. and p.m., approx. q 12 hours)

Singulair® Tablets, Chewable Tablets, and Granule Packets

Generic: Montelukast sodium

Description: Leukotriene receptor antagonist

Manufacturer: Merck & Co. Inc.

Indication: Prophylaxis and chronic treatment of asthma in patients 12 months and older; Prevention of exercised-induced bronchoconstriction in patients 15 years and older

Recommended dose: Patients 15 years and older: one 10 mg tablet daily at night; 6 to 14 years: one 5 mg chewable tablet daily at night; 2 to 5 years: one 4 mg chewable tablet or granule packet daily taken at night; 12 to 24 months: one 4 mg granule packet.

Symbicort®

Generic: Budesonide/formoterol fumarate inhalation powder

Description: Combination product

Manufacturer: AstraZeneca

Indication: For the long-term maintenance treatment of asthma in patients 12 years and older.

Recommended dose: One to two sprays orally twice daily

Theophylline

Description: Methylxanthine

Manufacturer: Various

Indication: Treatment of symptoms and reversible airflow obstruction associated with chronic asthma, chronic bronchitis, or COPD.

Recommended dose: Initial dose is 10 mg/kg/day with adjustments made to maintain a steady plasma level of 5 mcg/mL to 15 mcg/mL

Tilade® Inhaler

Note: Tilade is being discontinued. It will remain available until current supplies are depleted.

Generic: Nedocromil sodium inhalation aerosol

Description: Mast cell stabilizer

Manufacturer: King Pharmaceuticals Inc.

Indication: Maintenance therapy in the management of patients with mild-to-moderate asthma

Recommended dose: For patients 6 years and up, two inhalations qid

Ventolin® HFA Inhalation Aerosol

Generic: Albuterol sulfate

Description: Short-acting beta₂-agonist

Manufacturer: GlaxoSmithKline

Indication: Treatment and prevention of bronchospasm in with reversible obstructive airways disease, and for prevention of exercise-induced asthma

Recommended dose: Patients 4 years and older: two puffs repeated q 4 to 6 hours; for some patients, one puff may be sufficient

VoSpire ER™ Extended-Release Tablets

Generic: Albuterol sulfate

Description: Controlled released short-acting beta₂-agonist

Manufacturer: Dava

Pharmaceuticals Inc.

Indication: Relief of bronchospasm in patients 6 years and older with reversible obstructive airway disease

Recommended dose: Patients 12 years and up: 8 mg every 12 hours; 6 to 12 years: 4 mg every 12 hours

Xolair®

Generic: Omalizumab

Description: Humanized IgG1 monoclonal antibody

Manufacturer: Genentech Inc.

Indication: Relief of asthma in patients 12 years and older with moderate-to-severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are controlled inadequately with inhaled corticosteroids

Recommended dose: 150 mg to 375 mg administered subcutaneously every 2 weeks to 4 weeks

PHARMACEUTICAL LISTING

2009 BUYERS GUIDE

Xopenex[®] Inhalation Solution
Generic: Levalbuterol HCl
Description: Short-acting beta₂-agonist
Manufacturer: Sepracor Inc.
Indication: Treatment or prevention of bronchospasm in patients 6 years and older with reversible obstructive airways disease
Recommended dose: Patients 6 to 11 years: 0.31 mg tid by nebulization; 12 years and up: 0.63 mg tid by nebulization

Xopenex[®] HFA Inhaler
Generic: Levalbuterol HCl
Description: Short-acting beta₂-agonist
Manufacturer: Sepracor Inc.
Indication: For the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease
Recommended dose: 1 to 2 inhalations every 4 to 6 hours

Zyflo[®]
Generic: Zileuton tablets
Description: Leukotriene formation inhibitor
Manufacturer: Critical Therapeutics Inc.
Indication: Prevention and chronic treatment of asthma in patients 12 years and older
Recommended dose: 600 mg qid

Zyflo[®] CR
Generic: Zileuton extended release tablets
Description: Leukotriene formation inhibitor
Manufacturer: Critical Therapeutics Inc.
Indication: Prevention and chronic treatment of asthma in patients 12 years and older
Recommended dose: Two 600 mg tablets (1200 mg) bid

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Acetylcysteine Solution 10% and 20% USP
Description: Mucolytic agent
Manufacturer: Various
Indication: Adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions
Recommended dose: 3 to 5 mL of the 20% solution or 6 to 10 mL of the 10% solution diluted with an appropriate vehicle 3 to 4 times a day.

Advair[™] Diskus[®] 100/50, 250/50, 500/50
(See asthma section)

Albuterol Inhalation Aerosol
(See asthma section)

Albuterol Sulfate Inhalation Solution 0.5%
(See asthma section)

Albuterol Sulfate Inhalation Solution 0.083%
(See asthma section)

ATROVENT[™] HFA Inhalation Aerosol
Generic: Ipratropium bromide HFA
Description: Anticholinergic
Manufacturer: Boehringer Ingelheim
Indication: Maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema
Recommended dose: 2 puffs qid

Brovana[™] Inhalation Solution
Generic: Arformoterol tartrate
Description: Long-acting beta₂-agonist
Manufacturer: Sepracor Inc.
Indication: Twice daily, long-term maintenance treatment of bronchoconstriction in patients with COPD, which includes chronic bronchitis and emphysema.
Recommended dose: 15 mcg administered twice a day (a.m. and p.m.) by nebulization

Combivent[®] Inhalation Aerosol
Generic: Ipratropium bromide and albuterol sulfate
Description: Combination drug
Manufacturer: Boehringer Ingelheim
Indication: For patients with COPD on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator
Recommended dose: Two inhalations qid

DuoNeb[®] Inhalation Solution
Generic: Ipratropium bromide 0.5 mg and albuterol sulfate 3.0 mg
Description: Combination drug
Manufacturer: Dey
Indication: Treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator
Recommended dose: 3 mL vial qid by nebulization

Foradil[®] Aerolizer[™]
(See asthma section)

Ipratropium Bromide Inhalation Solution 0.02%
Description: Anticholinergic
Manufacturer: Dey
Indication: Maintenance treatment

of bronchospasm associated with COPD, including chronic bronchitis and emphysema
Recommended dose: 500 mcg (one vial) tid or qid by oral nebulization

Ipratropium bromide 0.5 mg and albuterol sulfate 3.0 mg /3mL Solution
Description: Combination drug
Manufacturer: Various
Indication: Treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator
Recommended dose: 3 mL vial qid by nebulization

Metaproterenol Sulfate (oral syrup and tablets)
(See asthma section)

Perforomist Inhalation Solution
Generic: Formoterol fumarate inhalation solution
Description: Solution for inhalation
Manufacturer: Dey
Indication: For the long term treatment of bronchoconstriction in COPD
Recommended dose: Twice-daily nebulization

Serevent[®] Diskus
(See asthma section)

Spiriva[®] HandiHaler[®]
Generic: Tiotropium bromide inhalation powder
Description: Anticholinergic
Manufacturer: Boehringer Ingelheim
Indication: Long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema
Recommended dose: The inhalation of the contents of one capsule once daily using the HandiHaler inhalation device

Theophylline
(See asthma section)

CYSTIC FIBROSIS

Acetylcysteine Solution 10% and 20% USP
Description: Mucolytic agent
Manufacturer: Various
Indication: Adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions
Recommended dose: 1 mL to 10 mL of 20% solution (or 2 mL to 20 mL 10% solution) nebulized q 6 to 8 hours

Pulmozyme[®] Inhalation Solution
Generic: Dornase alfa
Description: Recombinant human deoxyribonuclease
Manufacturer: Genentech Inc.
Indication: Management of cystic fibrosis patients to improve pulmonary function
Recommended dose: One single-use ampule inhaled once daily by nebulization

TOBI[®] Solution for Inhalation
Generic: Tobramycin
Description: Aminoglycoside antibiotic
Manufacturer: Novartis Pharmaceutical Corp.
Indication: Management of cystic fibrosis patients 6 years and older with *P. aeruginosa*
Recommended dose: 300 mg by nebulization bid for 28 days, 28 days off, repeat

INSOMNIA

Ambien[®]
Generic: Zolpidem tartrate
Description: Nonbenzodiazepine hypnotic
Manufacturer: sanofi-aventis U.S.
Indication: Short-term treatment of insomnia characterized by difficulties with sleep initiation
Recommended dose: 5 mg or 10 mg immediately before bedtime

Ambien-CR[®]
Generic: Zolpidem tartrate, controlled release
Description: Nonbenzodiazepine hypnotic
Manufacturer: sanofi-aventis U.S.
Indication: Short-term treatment of insomnia characterized by difficulties with sleep onset and/or maintenance
Recommended dose: 6.25 mg or 12.5 mg before bedtime

Butisol[®] Sodium, Tablets and Elixir
Generic: Butabarbital sodium
Description: Sedative, hypnotic
Manufacturer: Medpointe Pharmaceuticals
Indication: Insomnia
Recommended dose: Adults: as a daytime sedative, 15 to 30 mg tid or qid; as a hypnotic, 50 to 100 mg daily. Children: as a daytime sedative, 7.5 to 30 mg depending on age, weight, and degree of sedation required

Dalmane[®]
Generic: Flurazepam HCl
Description: Benzodiazepine hypnotic agent

Manufacturer: Valeant Pharmaceuticals International
Indication: For the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakening
Recommended dose: 15 mg or 30 mg before bedtime

Doral® 15 mg Tablets
Generic: Quazepam tablets
Description: Benzodiazepine hypnotic agent
Manufacturer: Questcor Pharmaceuticals Inc.
Indication: Short-term treatment of insomnia characterized by difficult in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings
Recommended dose: One tablet before bedtime

Edluar 5mg, 10mg Sublingual Tablet
Generic: Zolpidem sublingual tablets
Description: Non-benzodiazepine hypnotic
Manufacturer: Meda AB
Indication: Short-term treatment of insomnia characterized by difficulties in sleep initiation
Recommended dose: One tablet before bedtime

Estazolam
Description: Benzodiazepine hypnotic agent
Manufacturer: Various
Indication: Short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakening
Recommended dose: 1 mg or 2 mg at bedtime

Flurazepam HCl
Description: Benzodiazepine hypnotic agent
Manufacturer: Various
Indication: For the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakening
Recommended dose: 15 mg or 30 mg before bedtime

Halcion®
Generic: Triazolam
Description: Triazolobenzodiazepine hypnotic agent
Manufacturer: Pfizer Inc.
Indication: Short-term treatment of insomnia

Recommended dose: 0.125 mg or 0.25 mg before bedtime

LUNESTA™
Generic: Eszopiclone
Description: Nonbenzodiazepine hypnotic agent
Manufacturer: Sepracor Inc.
Indication: Insomnia
Recommended dose: 1 mg, 2 mg, or 3 mg before bedtime

Restoril™
Generic: Temazepam capsules
Description: Benzodiazepine hypnotic agent
Manufacturer: Mallinckrodt Inc.
Indication: Short-term treatment of insomnia
Recommended dose: 7.5 mg, 15 mg, 22.5 mg, or 30 mg before bedtime

Rozerem™
Generic: Ramelteon tablets
Description: Nonbenzodiazepine hypnotic agent
Manufacturer: Takeda Pharmaceuticals America Inc.
Indication: For treatment of insomnia characterized by difficulty with sleep onset
Recommended dose: One 8 mg tablet at bedtime

Somnote®
Generic: Chloral hydrate capsules USP 500 mg
Description: Hypnotic agent
Manufacturer: Breckenridge Pharmaceutical Inc.
Indication: Short-term treatment of simple insomnia
Recommended dose: Adults: 500 mg before retiring; Children: 50 mg/kg body weight

Sonata® Capsules
Generic: Zaleplon
Description: Nonbenzodiazepine hypnotic
Manufacturer: King Pharmaceuticals Inc.
Indication: Short-term treatment of insomnia
Recommended dose: 5 or 10 mg

Temazepam Capsules
Description: Benzodiazepine hypnotic agent
Manufacturer: Various
Indication: Short-term treatment of insomnia
Recommended dose: 15 mg or 30 mg before bedtime

Triazolam
Description: Triazolobenzodiazepine hypnotic agent

Manufacturer: Various
Indication: Short-term treatment of insomnia
Recommended dose: 0.125 mg or 0.25 mg before bedtime

ZolpiMist Oral Spray
Generic: Zolpidem oral spray
Description: Non-benzodiazepine hypnotic
Manufacturer: Novadel
Indication: Short-term treatment of insomnia characterized by difficult in falling asleep
Recommended dose: One spray (5 mg) or two sprays (10 mg) before bedtime

Zolpidem tartrate
Description: Nonbenzodiazepine hypnotic
Manufacturer: Various
Indication: Short-term treatment of insomnia characterized by difficulties with sleep initiation
Recommended dose: 5 mg or 10 mg immediately before bedtime

NARCOLEPSY/CATAPLEXY

Dexedrine®
Generic: Dextroamphetamine sulfate
Description: Amphetamine
Manufacturer: GlaxoSmithKline
Indication: Narcolepsy
Recommended dose: Adults: 5 mg to 60 mg daily in divided doses; 6 to 12 years: 5 mg daily

DextroStat®
Generic: Dextroamphetamine sulfate
Description: Amphetamine
Manufacturer: Shire US Inc.
Indication: Narcolepsy
Recommended dose: Patients 12 years and up 5 mg to 60 mg daily in divided doses. Give first dose on awakening; additional doses at intervals of 4 to 6 hours. Start with 10 mg daily, raise in increments of 10 mg at weekly intervals until optimal level is achieved; 6 to 12 years: 5 mg daily.

NUVIGIL®
Generic: Armodafinil tablets
Description: Central nervous system stimulant, analeptic
Manufacturer: Cephalon Inc.
Indication: Improve wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder
Recommended dose: For patients with OSAHS or narcolepsy, 150 mg

or 250 mg in a single dose in the morning. For patients with shift work sleep disorder, 150 mg given daily approximately 1 hour prior to the start of their work shift.
Note: In patients with OSAHS, doses up to 250 mg/day, given as a single dose, have been well-tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 150 mg/day dose.

Provigil®
Generic: Modafinil tablets
Description: Central nervous system stimulant, analeptic
Manufacturer: Cephalon Inc.
Indication: Improve wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder
Recommended dose: 100 mg to 200 mg once daily

Ritalin®
Generic: Methylphenidate hydrochloride tablets USP
Description: Mild central nervous system stimulant
Manufacturer: Novartis Pharmaceuticals Corp.
Indication: Narcolepsy
Recommended dose: Adults: 20 to 30 mg daily; 6 years and older: 5 mg bid

Xyrem® Oral Solution
Generic: Sodium oxybate
Description: Central nervous system depressant. (This drug only is available via Xyrem Success Program, a restricted distribution risk management program and registry to approved practitioners.)
Manufacturer: Jazz Pharmaceuticals Inc.
Indication: Treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy
Recommended dose: 4.5 g/day up to 9 g/day

NEONATAL RESPIRATORY DISTRESS SYNDROME

CAFCIT® Injection 20mg/mL and Oral Solution 20mg/mL
Generic: Caffeine citrate
Description: Central nervous system stimulant
Manufacturer: Bedford Laboratories
Indication: Short-term treatment of apnea of prematurity in infants 28 to 33 weeks old
Recommended dose: Initial dose:

PHARMACEUTICAL LISTING

2009 BUYERS GUIDE

1 mL/kg intravenously over 30 minutes; Maintenance dose: 0.25 mL/kg every 24 hours

CUROSURF® Intratracheal Suspension
Generic: Poractant alfa
Description: Pulmonary surfactant
Manufacturer: Dey
Indication: Treatment (rescue) of RDS in premature infants
Recommended dose: 2.5 mL/kg birth weight with subsequent doses of 1.25 mL/kg birth weight every 12 hours if needed

Infasurf® Intratracheal Suspension
Generic: Calfactant
Description: Pulmonary surfactant
Manufacturer: Forest Pharmaceuticals Inc.
Indication: Prevention of RDS in premature infants at high risk for RDS and for the treatment (rescue) of premature infants who develop RDS
Recommended dose: 3 mL/kg body weight at birth

Survanta® Intratracheal Suspension
Generic: Beractant
Description: Pulmonary surfactant
Manufacturer: Abbott Laboratories Inc.
Indication: Prevention and treatment (rescue) of RDS in premature infants
Recommended dose: 100 mg of phospholipids/kg birth weight (4 mL/kg)

PULMONARY HYPERTENSION

Epoprostenol sodium
Description: Prostacyclin analog
Manufacturer: Teva Parenteral Medicines Inc.
Indication: Long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Recommended dose: Chronic infusion should be initiated at 2 ng/kg/min and increased in increments of 2 ng/kg/min every 15 minutes or longer until dose-limiting pharmacologic effects are elicited or until a tolerance limit to the drug is established and further increases in infusion rate are not clinically warranted.

Flofan®
Generic: Epoprostenol sodium
Description: Prostacyclin analog
Manufacturer: GlaxoSmithKline
Indication: Long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Recommended dose: Chronic infusion should be initiated at 2 ng/kg/min and increased in increments of 2 ng/kg/min every 15 minutes or longer until dose-limiting pharmacologic effects are elicited or until a tolerance limit to the drug is established and further increases in infusion rate are not clinically warranted.

Letairis
Generic: Ambrisentan
Description: Type-A selective endothelin receptor antagonist
Manufacturer: Gilead Sciences Inc.
Indication: Treatment of pulmonary arterial hypertension in subjects with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening.
Recommended dose: Initial dose: 5 mg once daily. The dose may be increased to 10 mg once daily if the 5 mg dose is tolerated.

Remodulin™
Generic: Treprostinil sodium
Description: Prostacyclin analog
Manufacturer: United Therapeutics Corp.
Indication: Continuous subcutaneous infusion for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise
Recommended dose: Supplied in 20 mL vials in concentrations of 1.0 mg/mL, 2.5 mg/mL, 5.0 mg/mL, and 10.0 mg/mL. Infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated, the infusion rate should be reduced to 0.625 ng/kg/min.

Revatio® Tablets
Generic: Sildenafil citrate
Description: Phosphodiesterase type-5 (PDE5) inhibitor
Manufacturer: Pfizer Inc.
Indication: For the treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability
Recommended dose: One 20 mg tablet tid

Tracleer® Tablets
Generic: Bosentan
Description: Endothelin receptor agonist
Manufacturer: Actelion Pharmaceuticals US Inc.
Indication: Treatment of pulmonary arterial hypertension in patients with WHO class III or IV symptoms, to improve exercise ability and decrease the rate of clinical worsening
Recommended dose: 62.5 mg bid for 4 weeks, then increase to maintenance dose of 125 mg bid

Ventavis® Inhalation Solution
Generic: Iloprost
Description: Synthetic prostacyclin
Manufacturer: Actelion Pharmaceuticals US Inc.
Indication: Treatment of pulmonary arterial hypertension in patients with NYHA Class III or IV symptoms
Recommended dose: Inhalation of 2.5 mcg 6 to 9 times daily using either the Prodose® AAD® System or the I-neb™ AAD System

RESTLESS LEGS SYNDROME

Mirapex® 0.125 mg, 0.25 mg, 0.5 mg Tablets
Generic: Pramipexole dihydrochloride
Description: Nonergot dopamine agonist
Manufacturer: Boehringer Ingelheim
Indication: Treatment for those patients with moderate-to-severe primary RLS
Recommended dose: The recommended starting dose for RLS is 0.125 mg taken once daily, 2 to 3 hours before bedtime. For patients requiring additional symptomatic relief, the dose may be increased every 4 to 7 days.

Requip® Tablets
Generic: Ropinirole HCl
Description: Second-generation dopamine agonist
Manufacturer: GlaxoSmithKline
Indication: Treatment for those patients with moderate-to-severe primary RLS
Recommended dose: Adult starting dosage for RLS: 0.25 mg once daily, 1 to 3 hours before bedtime. After two days, the dosage can be increased to 0.5 mg once daily and to 1 mg once daily at the end of the first week of dosing, then titrated as needed to achieve efficacy. For RLS, the safety and effectiveness of doses greater than

4 mg once daily have not been established.

Ropinirole
Description: Second-generation dopamine agonist
Manufacturer: Various
Indication: Treatment for those patients with moderate-to-severe primary RLS
Recommended dose: Adult starting dosage for RLS is 0.25 mg once daily, 1 to 3 hours before bedtime. After two days, the dosage can be increased to 0.5 mg once daily and to 1 mg once daily at the end of the first week of dosing, then titrated as needed to achieve efficacy. For RLS, the safety and effectiveness of doses greater than 4 mg once daily have not been established.

SEVERE SEPSIS

Xigris®
Generic: Drotrecogin alfa (activated)
Description: Recombinant of human Activated Protein C
Manufacturer: Eli Lilly and Co.
Indication: Reduction of mortality in adult patients with severe sepsis who have a high risk of death
Recommended dose: Administered intravenously at an infusion rate of 24 mcg/kg/hr for a total of 96 hours

SMOKING CESSATION

Chantix™ 1 mg Tablets
Generic: Varenicline
Description: Nicotine receptor binding agent
Manufacturer: Pfizer Inc.
Indication: Aid to smoking cessation treatment
Recommended dose: One tablet bid

Commit® Lozenge, 2 mg and 4 mg
Generic: Nicotine
Manufacturer: GlaxoSmithKline
Indication: Aid to smoking cessation for relief of nicotine withdrawal symptoms
Recommended dose: One lozenge every 1 to 2 hours to start, reducing use by increasing duration between lozenges. Varies with "time to first cigarette."

Nicorette® Gum, 4 mg and 8 mg
Generic: Nicotine
Manufacturer: GlaxoSmithKline
Indication: Aid to smoking cessation for relief of nicotine withdrawal symptoms
Recommended dose: Slowly chew one piece of gum when urge to smoke occurs. Maximum dose is 60 mg/day.

Nicotine Transdermal Patch
Manufacturer: Various
Indication: Aid to smoking cessation for relief of nicotine withdrawal symptoms
Recommended dose: Apply one patch to skin daily and leave on for 16 to 24 hours for six to eight weeks.

Nicotrol® Inhaler
Generic: Nicotine inhalation system
Description: Nicotine replacement therapy
Manufacturer: Pfizer Consumer Healthcare
Indication: Aid to smoking cessation for the relief of nicotine withdrawal symptoms
Recommended dose: Initial treatment: 6 to 16 cartridges/day for up to 12 weeks with gradual reduction after 12 weeks as needed

Nicotrol® NS
Generic: Nicotine nasal spray
Description: Nicotine replacement therapy
Manufacturer: Pfizer Consumer Healthcare
Indication: Aid to smoking cessation for the relief of nicotine withdrawal symptoms
Recommended dose: One inhalation per nostril once or twice an hour (one dose = 1 mg nicotine), which can be increased to 80 sprays (40 mg) daily

ZYBAN™ Sustained Release Tablets
Generic: Bupropion hydrochloride
Description: Non-nicotine aid
Manufacturer: GlaxoSmithKline
Indication: Aid to smoking cessation treatment
Recommended dose: 300 mg/day given as 150 mg bid ■

ADVANCE thanks Michael J. McClusky, RPh, and Health Net Pharmaceutical Services, Rancho Cordova, Calif., for reviewing this guide.